1-15 of 15
Laurie Eliason
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Clinical Trials & Observations
Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott R. Solomon, Ingerid Weum Abrahamsen, Rachid C Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesus G. Berdeja, Sergio A Giralt, Anna Truppel-Hartmann, Yanping Chen, Xiaobo Zhong, Fan Wu, Julia Piasecki, Laurie Eliason, Devender S. Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa-Mckiver, Paula Rodriguez-Otero
Journal: Blood
Blood blood.2024024582.
https://doi.org/10.1182/blood.2024024582
Published: 2024
Includes: Supplemental data
Journal Articles

Long-term Follow-up from Qualitative Interviews of Patients with Relapsed or Refractory Large B-Cell Lymphoma on Their Treatment Experience While Enrolled in a Lisocabtagene Maraleucel Study

Pere Barba, Sally Lanar, Fei Fei Liu, Laurie Eliason, Kshawna Askew, Jennifer Devlen, Ulrika Furustrand, Ana Kostic
Journal: Blood
Blood (2023) 142 (Supplement 1): 7352.
https://doi.org/10.1182/blood-2023-178858
Published: 2023
Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Triple-Class-Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Who Received at Least 3 Lines of Prior Antimyeloma Regimens in the KarMMa-3 Phase 3 Randomized Controlled Trial

Michel Delforge, Krina K. Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S. Marshall, Bertrand Arnulf, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Sergio A. Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa-McKiver, Mark Cook, Paula Rodríguez Otero
Journal: Blood
Blood (2023) 142 (Supplement 1): 1003.
https://doi.org/10.1182/blood-2023-173849
Published: 2023
Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Paula Rodríguez Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Luciano Costa, Ravi Vij, Nizar J Bahlis, Philippe Moreau, Scott R. Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur S. Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesus G. Berdeja, Anna Truppel-Hartmann, Rashmi Bhatnagar, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa-McKiver, Sergio A. Giralt
Journal: Blood
Blood (2023) 142 (Supplement 1): 1028.
https://doi.org/10.1182/blood-2023-178933
Published: 2023
Journal Articles

Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL)

Guillaume Cartron, Alejandro Martin Garcia-Sancho, Juan Luis Reguera, Saurabh Dahiya, Shien Guo, Ling Shi, Laurie Eliason, Jinender Kumar, Thalia Farazi, Omotayo Fasan, Koji Izutsu
Journal: Blood
Blood (2023) 142 (Supplement 1): 668.
https://doi.org/10.1182/blood-2023-180175
Published: 2023
Journal Articles

Patient-Reported Outcomes from the MCL Cohort of the Phase 1, Seamless Design TRANSCEND NHL 001 Study of Lisocabtagene Maraleucel in Patients with R/R B-Cell NHL

Michael L. Wang, Leo I. Gordon, Alexandre V Hirayama, Matthew A Lunning, Ling Shi, Shien Guo, Ana Kostic, Laurie Eliason, Jinender Kumar, Maria Lia Palomba
Journal: Blood
Blood (2023) 142 (Supplement 1): 667.
https://doi.org/10.1182/blood-2023-180014
Published: 2023
Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial

Michel Delforge, Krina K. Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S. Marshall, Bertrand Arnulf, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Sergio A. Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa-McKiver, Mark Cook, Paula Rodriguez Otero
Journal: Blood
Blood (2023) 142 (Supplement 1): 96.
https://doi.org/10.1182/blood-2023-179152
Published: 2023
Journal Articles

Patient (pt) Experiences of Receiving Idecabtagene Vicleucel (Ide-Cel, bb2121) Versus Standard (Std) Regimens for the Treatment (Tx) of Relapsed/Refractory Multiple Myeloma (RRMM) in the Randomized, Controlled KarMMa-3 Clinical Trial: Analysis of Longitudinal Qualitative Interviews

Paula Rodríguez Otero, Krina K. Patel, Noopur S. Raje, Olga Moshkovich, Heather Gerould, Jennifer Devlen, Devender Dhanda, Laurie Eliason, Mark Cook, Mihaela Popa-McKiver, Salomon Manier
Journal: Blood
Blood (2023) 142 (Supplement 1): 2385.
https://doi.org/10.1182/blood-2023-173840
Published: 2023
Journal Articles

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Madhav V. Dhodapkar, Melissa Alsina, Jesus G. Berdeja, Krina K. Patel, Shambavi Richard, Ravi Vij, Xavier Leleu, Daniel N. Egan, P. Leif Bergsagel, Ran Reshef, Saad Z Usmani, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Laurie Eliason, Xiaobo Zhong, Chiara Greggio, Sinhan Tran, Maria Chaudhry, Marlene J. Carrasco-Alfonso, David S. Siegel
Journal: Blood
Blood (2023) 142 (Supplement 1): 2101.
https://doi.org/10.1182/blood-2023-173970
Published: 2023
Journal Articles

The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World

Attaya Suvannasankha, Thomas W. LeBlanc, Julia R. Correll, Chloe Carmichael, Boris Gorsh, Mona Martin, Helen Kitchen, Laurie Eliason, Madeleine Thursfield, Natalie Boytsov, Eva Brown Hajdukova, Mary Beth Lewis, Christine Mackay, Prani Paka, Alicia O'Neill, Sue Perera, Shivaranjani Naine, Alexa Molinari, Maya Hanna, David Kleinman
Journal: Blood
Blood (2022) 140 (Supplement 1): 13264–13266.
https://doi.org/10.1182/blood-2022-159637
Published: 2022
Journal Articles

Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?

Rakesh Popat, Ashraf Z. Badros, Shaji Kumar, Paula Rodríguez-Otero, Adam D. Cohen, Salomon Manier, Peter M. Voorhees, Francesca Gay, Robert M. Rifkin, Thomas Martin, Ajai Chari, Katja Weisel, Asim V. Farooq, Bennie H. Jeng, Wee Joo Chng, Hans C. Lee, Jesus Berdeja, Vinay Jadhav, Alessandra Tosolini, Laurie Eliason, Antonio Palumbo, Meletios A. Dimopoulos, Sagar Lonial, Suzanne Trudel, Paul G. Richardson, Evangelos Terpos
Journal: Blood
Blood (2021) 138 (Supplement 1): 2746.
https://doi.org/10.1182/blood-2021-152681
Published: 2021
Journal Articles

Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14

Malin Hultcrantz, David Kleinman, Pavandeep Ghataorhe, Astrid McKeown, Wei He, Thomas Ling, Roxanne C Jewell, Joseph Brunner, Julie Byrne, Laurie Eliason, Emma Scott, Joanna Opalinska
Journal: Blood
Blood (2021) 138 (Supplement 1): 1645.
https://doi.org/10.1182/blood-2021-152224
Published: 2021
Journal Articles

DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Sagar Lonial, MD FACP, Peter M. Voorhees, MD, Simona Degli Esposti, MD, Ira Gupta, MD, Joanna Opalinska, MD, Sandhya Sapra, PhD, Boris Gorsh, PharmD, Zangdong He, PhD, David M Kleinman, MD, Debra Schaumberg, OD, MPH, ScD, Angely Loubert, PharmD, MSc, Juliette Meunier, MSc, Antoine Regnault, PhD, Laurie Eliason, MPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–28.
https://doi.org/10.1182/blood-2020-140013
Published: 2020
Journal Articles

DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Suzanne Trudel, MD, Randy Davis, PhD, Nicole M. Lewis, MSc, Kalpana K. Bakshi, MSc, Bikramjit Chopra, PhD, Rocio Montes de Oca, PhD, Geraldine Ferron-Brady, PhD, Laurie Eliason, MPH, Brandon E. Kremer, MD PhD, Ira Gupta, MD, Frank S. Wu, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4.
https://doi.org/10.1182/blood-2020-139785
Published: 2020
Journal Articles

Patient-Reported Experiences during and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study

Laurie Eliason, MPH, Julia Correll, MPH, Mona Martin, MPA, Anna Cardellino, MPH, Joanna Opalinska, MD, Trisha Piontek, BSN, Boris Gorsh, PharmD, Sandhya Sapra, PhD, Rakesh Popat
Journal: Blood
Blood (2020) 136 (Supplement 1): 1.
https://doi.org/10.1182/blood-2020-139395
Published: 2020